Literature DB >> 19824073

Characterization of a WiT49 cell line derived orthotopic model of Wilms tumor.

Mei-Hong Li1, Harold Yamase, Fernando Ferrer.   

Abstract

Wilms tumor is the most common malignant renal tumor in children. However, to date no Wilms tumor mouse model is available due to the lack of Wilms tumor cell lines. Herein for the first time we report an orthotopic xenograft mouse model utilizing the recently described Wilms tumor cell line WiT49. It has a high tumor occurrence rate (85%) without metastasis. Hematoxylin and eosin staining showed it is subcapsular in location and mainly biphasic with stromal and epithelial components while blastemal component is unappreciable. This model provides the prerequisite for the screening and development of new anti-tumor agents for Wilms tumor. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh：

Year:  2010        PMID： 19824073      PMCID： PMC2834252          DOI： 10.1002/pbc.22205

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  18 in total

1.  Wilms tumor and cardiomyopathy.

Authors:  Monika M Trebo; Georg Mann; Michael Dworzak; Andreas Zoubek; Helmut Gadner
Journal:  Med Pediatr Oncol       Date:  2003-12

2.  Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.

Authors:  S Z Soffer; J T Moore; E Kim; J Huang; A Yokoi; C Manley; K O'Toole; C Stolar; W Middlesworth; D J Yamashiro; J J Kandel
Journal:  J Pediatr Surg       Date:  2001-08       Impact factor: 2.545

3.  Late effects in children treated with radiation therapy for Wilms' tumor.

Authors:  A C Paulino; B C Wen; C K Brown; R Tannous; N A Mayr; W K Zhen; G J Weidner; D H Hussey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-03-15       Impact factor: 7.038

4.  Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group.

Authors:  Daniel M Green; Eve M Peabody; Bin Nan; Susan Peterson; John A Kalapurakal; Norman E Breslow
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

5.  Osteopenia in survivors of Wilms tumor.

Authors:  Fahad Othman; Chun-Yuan Guo; Colin Webber; Stephanie A Atkinson; Ronald D Barr
Journal:  Int J Oncol       Date:  2002-04       Impact factor: 5.650

Review 6.  One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.

Authors:  J Fogh; J M Fogh; T Orfeo
Journal:  J Natl Cancer Inst       Date:  1977-07       Impact factor: 13.506

7.  Derivation and characterization of a Wilms' tumour cell line, WiT 49.

Authors:  Jennifer Alami; Bryan R Williams; Herman Yeger
Journal:  Int J Cancer       Date:  2003-11-10       Impact factor: 7.396

8.  Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.

Authors:  Tsai-Kun Li; Peter J Houghton; Shyamal D Desai; Parima Daroui; Angela A Liu; Eszter S Hars; Alexander L Ruchelman; Edmond J LaVoie; Leroy F Liu
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

9.  Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.

Authors:  Jason S Frischer; Jianzhong Huang; Anna Serur; Angela Kadenhe-Chiweshe; Kimberly W McCrudden; Kathleen O'Toole; Jocelyn Holash; George D Yancopoulos; Darrell J Yamashiro; Jessica J Kandel
Journal:  Int J Oncol       Date:  2004-09       Impact factor: 5.650

10.  Regression of established tumors and metastases by potent vascular endothelial growth factor blockade.

Authors:  Jianzhong Huang; Jason S Frischer; Anna Serur; Angela Kadenhe; Akiko Yokoi; Kimberly W McCrudden; Tamara New; Kathleen O'Toole; Stephanie Zabski; John S Rudge; Jocelyn Holash; George D Yancopoulos; Darrell J Yamashiro; Jessica J Kandel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-12       Impact factor: 11.205
View more
  5 in total

1.  Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

Authors:  Aleksandra Bielen; Gary Box; Lara Perryman; Lynn Bjerke; Sergey Popov; Yann Jamin; Alexa Jury; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Vincent Romanet; Sebastien Jeay; Florence I Raynaud; Francesco Hofmann; Simon P Robinson; Suzanne A Eccles; Chris Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-23       Impact factor: 11.205

2.  Monitoring therapy with MEK inhibitor U0126 in a novel Wilms tumor model in Wt1 knockout Igf2 transgenic mice using 18F-FDG PET with dual-contrast enhanced CT and MRI: early metabolic response without inhibition of tumor growth.

Authors:  Leo G Flores; Hsin-Hsien Yeh; Suren Soghomonyan; Daniel Young; James Bankson; Qianghua Hu; Mian Alauddin; Vicki Huff; Juri G Gelovani
Journal:  Mol Imaging Biol       Date:  2013-04       Impact factor: 3.488

3.  SIX2 Effects on Wilms Tumor Biology.

Authors:  Janene Pierce; Andrew J Murphy; Alexis Panzer; Christian de Caestecker; Gregory D Ayers; David Neblett; Kenyi Saito-Diaz; Mark de Caestecker; Harold N Lovvorn
Journal:  Transl Oncol       Date:  2014-12       Impact factor: 4.243

4.  Senescence Process in Primary Wilms' Tumor Cell Culture Induced by p53 Independent p21 Expression.

Authors:  Korkiat Theerakitthanakul; Jeerasak Khrueathong; Jirasak Kruatong; Potchanapond Graidist; Pritsana Raungrut; Kanita Kayasut; Surasak Sangkhathat
Journal:  J Cancer       Date:  2016-09-02       Impact factor: 4.207

5.  The Iroquois homeobox proteins IRX3 and IRX5 have distinct roles in Wilms tumour development and human nephrogenesis.

Authors:  Linda Holmquist Mengelbier; Simon Lindell-Munther; Hiroaki Yasui; Caroline Jansson; Javanshir Esfandyari; Jenny Karlsson; Kimberly Lau; Chi-Chung Hui; Daniel Bexell; Sevan Hopyan; David Gisselsson
Journal:  J Pathol       Date:  2018-11-29       Impact factor: 7.996
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.